Cabaletta Bio Inc. has outlined its 2026 strategic priorities centered on advancing the development and planned launch of rese-cel (resecabtagene autoleucel) for autoimmune diseases. The company plans to focus on enrolling its pivotal myositis trial to support a planned Biologics License Application (BLA) submission in 2027, including exploring an outpatient dosing option with a single weight-based dose. Cabaletta intends to confirm the readiness of its automated, scalable Cellares manufacturing platform, with clinical manufacturing data expected in the first half of 2026. The company also aims to generate new clinical data on rese-cel without preconditioning and at higher doses in various autoimmune indications, with complete Phase 1/2 data in lupus, scleroderma, and myasthenia gravis anticipated in the first half of 2026. Additionally, Cabaletta is prioritizing a no preconditioning regimen for registrational studies in systemic lupus erythematosus and lupus nephritis, pending dose-ranging data. The company’s strategy includes translating registrational pathways with rese-cel into a broader pipeline for other autoimmune diseases and expanding access through automated manufacturing and outpatient treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623435-en) on January 12, 2026, and is solely responsible for the information contained therein.